Human in vitro induced T regulatory cells and memory T cells share common demethylation of specific FOXP3 promoter region by Philippe Bégin et al.
Bégin et al. Clin Transl Allergy  (2015) 5:35 
DOI 10.1186/s13601-015-0079-2
BRIEF COMMUNICATION 
Human in vitro induced T regulatory 
cells and memory T cells share common 
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Abstract 
Background: The FOXP3 gene is the master regulator for T regulatory cells and is under tight DNA methylation 
control at the Treg specific demethylated region (TSDR) in its first intron. This said, methylation of its promoter region, 
the significance of which is unknown, has also been associated with various immune-related disease states such 
as asthma, food allergy, auto-immunity and cancer. Here, we used induced T regulatory cells (iTreg) as a target cell 
population to identify candidate hypomethylated CpG sites in the FOXP3 gene promoter to design a DNA methyla-
tion quantitative assay for this region.
Findings: Three CpG sites at the promoter region showed clear demethylation pattern associated with high FOXP3 
expression after activation in presence of TGFβ and were selected as primary targets to design methylation-depend-
ent RT-PCR primers and probes. We then examined the methylation of this ‘inducible-promoter-demethylated-region’ 
(IPDR) in various FOXP3+ T cell subsets. Both naïve and memory thymic-derived Treg cells were found to be fully 
demethylated at both the IPDR and TSDR. Interestingly, in addition to iTregs, both CD25− and CD25lo conven-
tional memory CD4+CD45RA− T cells displayed a high fraction of IPDR demethylated cells in absence of TSDR 
demethylation.
Conclusion: This implies that the fraction of memory T cells should be taken in account when interpreting FOXP3 
promoter methylation results from clinical studies. This approach, which is available for testing in clinical samples 
could have diagnostic and prognostic value in patients with immune or auto-inflammatory diseases.
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Findings
The FOXP3 gene plays a key role in regulating the 
immune response and its expression occurs under tight 
epigenetic control [1]. Notably, DNA demethylation of 
the ‘Treg-specific-demethylated-region’ (TSDR), located 
on the 2nd conserved non-coding sequence of FOXP3 
(CNS2), is a sine qua non modification found in thymic-
derived T regulatory cells (tTregs—formerly known as 
nTregs) [2]. TSDR demethylation results in stable and 
high FOXP3 expression and suppressive function in 
tTregs. Using a modified RT-PCR approach, the amount 
of TSDR hypomethylation can be precisely measured 
from whole DNA providing a highly accurate quantita-
tive biomarker to identify tTregs within whole blood, 
PBMCs or tissue samples [3].
This said, epigenetic studies using pyrosequencing have 
also associated other loci on the FOXP3 gene, such as its 
promoter region, with various immune-related disease 
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states such as asthma [4], food allergy [5], auto-immunity 
[6, 7] and cancer [8]. Furthermore, the FOXP3+ T cell 
compartment comprises other cell subsets with methyl-
ated TSDR which have variable suppressive function [9] 
and FOXP3 can be transiently expressed by any non-
suppressive T conventional (Tconv) cells upon activation 
[10]. In mice, knocking-out the CNS1 results in a loss of 
peripheral tolerance with allergy and maternal-fetal con-
flict despite functional tTregs showing the importance 
of other control regions on FOXP3 and of non-tTreg 
FOXP3+ subsets to regulate the immune response [11]. 
We hypothesized that FOXP3+ subset-specific DNA 
methylation sites could be identified outside of the TSDR 
and used additively to design a more comprehensive, 
high-throughput assay to characterize the FOXP3+ T 
cell population in clinical samples. Characterizing the 
FOXP3+ T cell populations could have a high impact in 
monitoring and treating many diseases, including those 
diseases with autoimmunity, cancer, and allergy.
Given their potential clinical relevance and lack of 
available markers, we performed studies using induced 
Tregs (iTreg) as a target cell population to identify can-
didate hypomethylated CpG sites. iTregs are typically 
generated in  vitro from naïve T cells with TCR-medi-
ated stimulation in the presence of tumor growth factor 
(TGF)-β and interleukin (IL)-2. The expression of FOXP3 
from the resulting iTreg population is very high but these 
cells remain fully methylated at the TSDR [1]. In humans, 
their suppressive function is not reliable although the 
addition of retinoic acid to the induction protocol has 
been reported to increase the stability of FOXP3 expres-
sion and of the suppressive function [12, 13].
Briefly, naïve T cells were cell-sorted (BD FACSAria II®) 
from healthy control peripheral blood on consented adult 
blood bank donors as CD4+CD45RA+CD62L+CD25− 
and put in culture in AIM V medium (Life Technolo-
gies®) with 100  U/mL IL-2 (BD Pharmingen®), 10  ng/
mL TGF-β1 (R&D Systems®), and/or 100  nM ATRA 
(Sigma-Aldrich®) and anti-CD3/CD28 mAbs Dynabeads 
(Life Technologies®) at a bead:cell ratio of 1:20 (Fig. 1a). 
Beads were removed with magnet at day 4 and cells were 
washed and re-plated with fresh medium with IL-2 at 
100 UI/L. Cells were fixed at day 7 and sorted based on 
their intracellular expression of FOXP3 (Fig. 1b–d). DNA 
was extracted and bisulfite treated for pyrosequencing 
of the FOXP3 promoter and three conserved noncoding 
sequences regions (Fig. 1e).
Interestingly, three CpG sites at the promoter regions 
(at positions −126, −77 and −56 from transcription start 
site) showed clear demethylation pattern associated with 
high FOXP3 expression after activation in presence of 
TGFβ (Fig. 1e). There were no changes in demethylation 
of TSDR or other CNS regions. Addition of retinoic acid 
to TGFβ did not impact the demethylation of any CpG 
sites in the FOXP3 locus compared to TGFβ alone. The 
three CpG sites in the promoter region were selected as 
primary targets to design primers and probes to quantify 
the methylation of this ‘inducible-promoter-demethyl-
ated-region’ (IPDR) using the same method established 
for the TSDR (Fig. 1f ) [3, 14].
The specificity and sensitivity of the assay was first con-
firmed by using methylated and demethylated synthetic 
plasmid sequences (Fig. 1g, h) and then validated in cell 
populations with high methylation of the IPDR, as tested 
by pyrosequencing (i.e. granulocytes, monocytes, B cells 
and NK cells). To validate its quantitative value in sam-
ples, the IPDR assay was performed on whole T cells 
from an iTreg induction culture at baseline and day 7. A 
low percentage of naïve T cells showed IPDR demethyla-
tion at baseline. At day 7, in the presence of TGF-β, the 
fraction of IPDR demethylation was increased and the 
increment was correlated with the increased frequency 
of cells expressing high levels of FOXP3 protein (Fig. 2a).
To investigate the distribution of IPDR demethyla-
tion in FOXP3+ T cell subsets we applied the assay to 
fresh peripheral T cell populations based on CD25 and 
CD45RA expression according to previously described 
classification [1]. Both naïve and memory tTreg cells 
(Fig.  2a) were found to be fully demethylated at both 
the IPDR and TSDR. Interestingly, both CD25− and 
CD25lo conventional memory CD4+ T cells displayed a 
high fraction of IPDR demethylated cells (Fig. 2b). Thus, 
while TSDR demethylation is required for sustained 
high expression of FOXP3 in tTregs, IPDR demethyla-
tion is associated with a wide range of (possibly tran-
sient) FOXP3 protein expression in antigen-experienced 
(See figure on next page.) 
Fig. 1 FOXP3 promoter RT-PCR assay design. Naïve T cells (CD4+CD45RA+CD62L+CD25−) were sorted from CD4 enriched buffy coats (a, red 
gate) and put in culture with IL-2 and CD3/CD28 stimulation in medium alone (b), in the presence of TGF-β (c) or both TGF-β and retinoic acid (d). 
At day 7, cells were sorted based on FOXP3 expression. FOXP3high (green gates) and FOXP3low samples (red gates), as well as baseline naïve tTreg con-
trols (a, green gate) were pyrosequenced at the promoter and three conserved non-coding sequence regions of the FOXP3 gene (e). Promoter CpG 
sites at positions −126, −77 and −56 from transcription start site showed the greatest differential methylation in FOXP3high TGF-induced T cells 
(iTregs) (indicated with arrows). These sites were selected to design primers and RT-PCR probes specific for their methylation status (f). Specificity of 
methylated and unmethylated RT-PCR primers and probes was validated using unmethylated (g) and methylated (h) plasmid standards dilutions at 
31,250, 6250, 1250, 250 and 50 copy numbers per reaction
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T cells, ranging from negative to low protein expression 
in memory T cells, to high expression in iTregs. The high 
expression of FOXP3 protein in iTreg could be due to the 
additional effect of epigenetic modifications such as his-
tone modifications, as suggested in mice [15]. Inversely, 
in non-activated CD25−/lo memory T cells, the FOXP3 
protein could be down-regulated at the post-translational 
level by STUB1-mediated ubiquitination and proteaso-
mal degradation of the protein, which is induced by pro-
inflammatory stimuli (IL-1, IL-6, LPS) [16].
Such an ability to express and modulate low levels of 
FOXP3 with IPDR demethylation could be important for 
the homeostatic control of the antigen-experienced T cell 
population. Knocking down FOXP3 in non-regulatory T 
cells with siRNA demonstrated FOXP3 expression is crit-
ical for limiting cellular proliferation and cytokine pro-
duction (intrinsic regulation) [10].
This said, the variable demethylation of the IPDR in 
T cell subsets means that it cannot be used to quantify 
subsets from unfractioned blood like the TSDR assay. 
Fig. 2 RT-PCR quantification of FOXP3 promoter and TSDR demethylation in CD4 T cell subpopulations. Culture of naïve CD4 T cells for 7 days with 
IL-2 and CD3/CD28 stimulation induced the demethylation of the FOXP3 promoter in the presence of TGF-β and/or retinoic acid (iTregs) but not 
with medium alone (a). FOXP3 promoter demethylation in absence of TSDR demethylation was also found to be a hallmark of CD45RA−CD25−
CD4+ memory T cells and CD45RA−CD25lowCD4+ “Treg-like” T conventional cells, but not of CD45RA+CD62L+CD4+ naïve or CD45RA+CD62L−
CD4+ effector T cells (b)
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Controlling for CD45 expression in CD3 positive T cells 
may help improve test interpretation on mixed popula-
tion sample but it is insufficient to account for all the 
inter-individual variability (data not shown) which may 
also stem demethylation of IPDR in effector (<30  %), 
naïve T cells (<20 %) which despite being low does con-
tribute to the whole amount of demethylated DNA. This 
raises questions with regards to previous associations of 
FOXP3 promoter demethylation with immune disease 
states which were based on unfractioned blood analy-
ses, which may need to be revisited by measuring IPDR 
demethylation in sorted specific T cell subsets. Further in 
depth analyses of IPDR demethylation in T cell subsets 
in large cohorts will also be needed to provide reference 
values for such analyses. Better characterization of IPDR 
demethylation in various subsets may eventually pro-
vide surface markers that will allow its interpretation in 
unfractioned samples.
In summary, we have identified an inducible promoter 
demethylated region (IPDR) of FOXP3 and designed a 
quantitative assay to accurately measure its methylation 
which is available for testing in clinical samples. Since 
IPDR demethylation in absence of TSDR demethylation 
is a feature of both iTregs and memory T cells, its use will 
minimally require taking in account the fraction of cell 
subsets in a given mixed sample, or ideally, pre-sorting 
of cell subsets prior to analysis. This approach could have 
diagnostic and prognostic value in patients with immune 
or auto-inflammatory diseases.
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